11 citations,
January 1991 in “Urology” New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.
1 citations,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
8 citations,
August 2021 in “Fertility and Sterility” Treatments for enlarged prostate can cause problems with ejaculation, and less invasive options might preserve sexual function better.
6 citations,
January 2020 in “The Aging Male” Testosterone replacement therapy improved blood sugar and fat levels without raising prostate cancer risk in Japanese men with low testosterone.
15 citations,
October 2014 in “Journal of Investigative Dermatology” New treatments targeting the Hedgehog pathway can help treat advanced skin cancer but may have side effects and their effectiveness in early stages is unknown.
30 citations,
June 1988 in “Journal of Steroid Biochemistry” Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.
1 citations,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
45 citations,
January 2008 in “Drugs” Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.
9 citations,
January 2018 in “Journal of the European Academy of Dermatology and Venereology” A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.
411 citations,
April 2010 in “Gastroenterology” Targeting colon cancer stem cells might lead to better treatment results.
88 citations,
July 2014 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
44 citations,
September 2014 in “Cell Death & Differentiation” Tumor suppressors help control inflammation in cancer and restoring their function could lead to new treatments.
103 citations,
June 2018 in “International Journal of Molecular Sciences” FGF signaling is a promising target for developing treatments for wounds, metabolic diseases, and cancer.
38 citations,
October 2014 in “Current Opinion in Endocrinology, Diabetes and Obesity” 5-alpha reductase deficiency leads to male sexual development issues and treatments like finasteride help with prostate enlargement and hair loss.
16 citations,
January 2000 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.
13 citations,
May 2018 in “Urologic Oncology: Seminars and Original Investigations” Finasteride does not prevent bladder cancer.
6 citations,
August 2013 in “한국응용생명화학회지” Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.
February 2024 in “BioMetals” Heavy metals like arsenic, cadmium, and lead can increase cancer risk and worsen outcomes.
21 citations,
March 2019 in “Critical Reviews in Clinical Laboratory Sciences” The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
December 2018 in “Actas urológicas españolas” 5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.
66 citations,
January 2001 in “Vitamins and hormones” Androgen receptors are key for development and health, affecting conditions like prostate cancer and male pattern baldness.
7 citations,
April 2019 in “The Journal of Steroid Biochemistry and Molecular Biology” 11α-Hydroxyprogesterone is changed into different substances by certain enzymes and may play a role in prostate cancer.
2 citations,
November 2017 in “Elsevier eBooks” Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.
130 citations,
November 2017 in “Frontiers in Immunology” The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.
2 citations,
March 2012 in “Current opinion in urology” 5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
2 citations,
June 2022 in “Molecules” Connarus semidecandrus Jack extract promotes hair growth and thickness, reduces prostate cancer cell growth, and could potentially be used as a treatment for hair loss.
61 citations,
May 2010 in “Integrative Cancer Therapies” There is no clear recommendation for using selenium in cancer patients; it may be beneficial to correct low selenium levels before treatment.
51 citations,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
29 citations,
October 2020 in “eLife” Higher testosterone levels can increase the risk of certain diseases like type 2 diabetes in women and prostate cancer in men, but can also protect against autoimmune diseases and hair loss. It also affects body fat and bone density.
24 citations,
February 2012 in “Prostate cancer and prostatic diseases” 5α-reductase inhibitors help shrink the prostate, improve urinary symptoms, and may reduce prostate cancer risk.